1007 Accuracy of end of treatment 18F-FDG PET for predicting relapse in patients with Hodgkin's disease (HD) and Non-Hodgkin's lymphoma (NHL)

G.Jerusalem; V.Warland; Y.Beguin; R.Hustinx; M.F.Fassotte; J.Foidart-Willems; G.Fillet

首页> 外文期刊>European Journal of Cancer Supplements >1007 Accuracy of end of treatment 18F-FDG PET for predicting relapse in patients with Hodgkin's disease (HD) and Non-Hodgkin's lymphoma (NHL)

【24h】

1007 Accuracy of end of treatment 18F-FDG PET for predicting relapse in patients with Hodgkin's disease (HD) and Non-Hodgkin's lymphoma (NHL)

机译：1007治疗末期18F-FDG PET预测霍奇金病（HD）和非霍奇金淋巴瘤（NHL）患者复发的准确性

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2003年第5期|共1页
作者
G.Jerusalem; V.Warland; Y.Beguin; R.Hustinx; M.F.Fassotte; J.Foidart-Willems; G.Fillet;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 1007 Accuracy of end of treatment 18F-FDG PET for predicting relapse in patients with Hodgkin's disease (HD) and Non-Hodgkin's lymphoma (NHL) [J] . G.Jerusalem, V.Warland, Y.Beguin, European Journal of Cancer Supplements . 2003,第5期

机译：1007治疗末期18F-FDG PET预测霍奇金病（HD）和非霍奇金淋巴瘤（NHL）患者复发的准确性
2. Positive Pre-Allogeneic Hematopoietic Cell Transplantation (alloHCT) PET Scan in Patients with Non-Hodgkin Lymphoma (NHL) Predicts Higher Risk of Relapse but Has No Impact on Survival [J] . Bachanova Veronika, Burns Linda J., Ahn Kwang Woo, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2015,第2Suppla1期

机译：非霍奇金淋巴瘤（NHL）患者的异基因造血细胞移植前阳性（alloHCT）PET扫描预测复发风险更高，但对生存率没有影响
3. A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin’s lymphoma following treatment with iodine-131-rituximab radio-immunotherapy | Haematologica [J] . Mark J. Bishton, Rodney J. Hicks, David A. Westerman, Haematologica . 2008,第5期

机译：碘131-利妥昔单抗放射免疫疗法治疗复发性惰性非霍奇金淋巴瘤患者18 [F] -FDG-PET和分子应答的单独预测能力的前瞻性研究血液学
4. Development of Single Domain Antibodies for Diagnosis and Treatment of Naturally Occurring Canine Lymphoma: An Animal Model for Human Non-Hodgkin Lymphoma [C] . Joana Dias, Solange Gil, Belmira Carrapico, PEGS . 2015

机译：天然犬淋巴瘤诊断和治疗单结构域抗体的发展：人非霍奇金淋巴瘤的动物模型
5. Risk of Depressive or Anxiety Disorders in Commercially Insured Patients with Non-Hodgkin Lymphoma (NHL) in the US: A Retrospective Analysis [D] . Sun, Lucille 2017

机译：美国非霍奇金淋巴瘤（NHL）商业保险患者发生抑郁或焦虑症的风险：回顾性分析
6. Pre-treatment partial-volume-corrected TLG is the best predictor of overall survival in patients with relapsing/refractory non-hodgkin lymphoma following radioimmunotherapy [O] . Raheleh Taghvaei, Mahdi Zirakchian Zadeh, Reza Sirous, 2018

机译：放射免疫治疗后复发/难治性非霍奇金淋巴瘤患者的治疗前进行部分体积校正的TLG是总体生存率的最佳预测指标
7. The clinical use of LMP2-specific cytotoxic T lymphocytes for the treatment of relapsed EBV +ve Hodgkin disease (HD) and non-Hodgkin lymphoma (NHL) [O] . Bollard C.M., Buza E., Huls H., 2006

机译：LMP2特异性细胞毒性T淋巴细胞在治疗复发性EBV + ve霍奇金病（HD）和非霍奇金淋巴瘤（NHL）中的临床应用

1007 Accuracy of end of treatment 18F-FDG PET for predicting relapse in patients with Hodgkin's disease (HD) and Non-Hodgkin's lymphoma (NHL)

著录项

相似文献

相关主题

期刊订阅